IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
#Acquired-by #Management Changes #Investment
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
#Public Trading #Acquisition
Kadimastem plans listing on Nasdaq through merger
#Acquired-by #Public Trading #Management Changes
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
#Acquired-by #Public Trading #Investment
Kadimastem Receives Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
#Investment #Partners
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
#Investment #Partners
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
#Investment #Expand
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
#Partners, Investment
iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
#Partners #Investment
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
#Partners #Investment
Kadimastem Receives US Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
#Partners #Investment
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
#Customers #Partners #Investment
Kadimastem Granted European Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
undefined
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation | MarketScreener
#Partners
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
#Partners #Investment
Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS
#Customers #Expand
Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS | News Direct
#Customers
AstroRx safe and slows ALS progression in Phase 1/2 clinical trial...
#Customers
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for the Treatment of ALS
#Investment #Expand #Partners
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for the Treatment of ALS | News Direct
#Customers
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational
Medicine
#Customers
Kadimastem Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
#Customers
Kadimastem Awarded Patent In Australia For Its Astrorx® Tech...
#Investment #Expand
Kadimastem Announces It Raised Appx 7.5 Million NIS By Right...
#Investment
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
#Investment #Expand
Kadimastem and iTolerance's Proposed Collaboration Further Strengthened With Receipt of US $1 Million BIRD Foundation Gran | News Direct
#Investment
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory
undefined
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory
#Customers #Partners #Management Changes
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory | BioSpace
#Customers #Partners
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
#Customers
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells News Direct
#Partners
קדימהסטם מקבלת מענק של 10 מיליון ש"ח מהרשות לחדשנות
#Investment
Kadimastem seeks Nasdaq listing, raises $3.2m from ILEX
#Investment #Public Trading
Kadimastem Raises $5 million In Private Placement News Direct
#Investment
פרופ' מישל רבל, בעל השליטה בקדימהסטם מימש אופציות בהיקף של כ-3.5 מיליון שקל למניות
#Investment
Kadimastem Raises NIS 22.3 Million ($6.8 Million) with a Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement News Direct
#Investment
https://www.jpost.com/health-science/promising-stem-cell-based-drug-for-treatment-of-als-receives-patent-661535
#Customers
Kadimastem hopes to turn corner with new management
#Management Changes
לאחר התפטרות המנכ"ל: מאבקי שליטה בקדימהסטם בין רבל לדח"צים
#Management Changes
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS
#Customers
Kadimastem reports positive ALS cell therapy results
#Customers
Stem cell co Kadimastem reports positive ALS results
#Investment
Israeli company plans to make insulin injections obsolete
#Customers
Israeli and French Biotech Companies Partner to Fight Diabetes With Bio-Artificial Pancreas
#Partners #Investment
https://www.pehub.com/2018/10/israeli-biotech-firm-kadmastem-procures-5-15-mln/
undefined
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
#Customers
Kadimastem jumps on Merck Serono collaboration
#Partners